Advances in management of thyroid cancer

Current Problems in Surgery

Volumn 50, Issue 6, 2013, Pages 241-289

  Jin, Judy ^a   Phitayakorn, Roy ^a   Wilhelm, Scott M ^a   McHenry, Christopher R ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; CALCITRIOL; CALCIUM CARBONATE; DOXORUBICIN; GEFITINIB; IODINE 131; LEVOTHYROXINE; LITHIUM; MOSATENIB; PLATINUM COMPLEX; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT THYROTROPIN; RETINOIC ACID; ROSIGLITAZONE; SORAFENIB; TAXANE DERIVATIVE; THYROTROPIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ARTICLE; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIATED THYROID CANCER; DISEASE SPECIFIC SURVIVAL; DISTANT METASTASIS; DRUG DOSE REDUCTION; DRUG MEGADOSE; ECHOGRAPHY; EXTERNAL BEAM RADIOTHERAPY; FAMILY HISTORY; FINE NEEDLE ASPIRATION BIOPSY; FOLLICULAR THYROID CANCER; HISTOPATHOLOGY; HUMAN; HURTHLE CELL CARCINOMA; HYPERTHYROIDISM; HYPOTHYROIDISM; LUNG METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; MOLECULAR PATHOLOGY; OVERALL SURVIVAL; PAPILLARY THYROID CANCER; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RADIATION EXPOSURE; RECURRENCE RISK; SOLID TUMOR; SURGICAL APPROACH; SURVIVAL RATE; SURVIVAL TIME; THYMECTOMY; THYROID CANCER; THYROID NODULE; THYROIDECTOMY; TUMOR INVASION; UNITED STATES;

ADULT; AGED; COMBINED MODALITY THERAPY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; UNITED STATES; WORLD HEALTH;

EID: 84877701828     PISSN: 00113840     EISSN: 15356337     Source Type: Journal    
DOI: 10.1067/j.cpsurg.2013.02.001     Document Type: Article

References (272)

1. Eheman C., Henley S.J., Ballard-Barbash R., et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118:2338-2366.
2. American Cancer Society. 'Cancer facts and figures'. 〈〉; 2012. http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer- key-statistics.
3. Al-Hamdan N., Ravichandran K., Al-Sayyad J., et al. Incidence of cancer in Gulf Cooperation Council Countries, 1998-2001. East Mediterr Health J 2009, 15:600-611.
4. Jung K.W., Park S., Kong H.J., et al. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2009. Cancer Res Treat 2012, 44:11-24.
5. Kilfoy B.A., Zheng T., Holford T.R., et al. International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 2009, 20:525-531.
6. Enewold L., Zhu K., Ron E., et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009, 18:784-791.
7. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. J Am Med Assoc 2006, 295:2164-2167.
8. Chen A.Y., Jemal A., Ward E.M. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009, 115:3801-3807.
9. Leitzmann M.F., Brenner A., Moore S.C., et al. Prospective study of body mass index, physical activity and thyroid cancer. Int J Cancer 2010, 126:2947-2956.
10. Zhao G., Wang Z., Zhou H., Zhao Q. Burdens of PBBs, PBDEs, and PCBs in tissues of the cancer patients in the E-waste disassembly sites in Zhejiang, China. Sci Total Environ 2009, 407:4831-4837.
11. Ries L.A., Eisner M.P., Kosary C.L. Seer Cancer Statistics Review, 1975-2001 2001, National Cancer Institute, Bethesa, MD.
12. Cramer J.D., Fu P., Harth K.C., Margevicius S., Wilhelm S.M. Analysis of the rising incidence of thyroid cancer using the surveillance, epidemiology and end results National Cancer Data Registry. Surgery 2010, 148:1147-1152. [discussion 52-3].
13. Jin J., Machekano R., McHenry C.R. The utility of preoperative serum thyroid-stimulating hormone level for predicting malignant nodular thyroid disease. Am J Surg 2010, 199:294-297. [discussion 98].
14. Furukawa K., Preston D., Funamoto S., et al. Long-term trend of thyroid cancer risk among Japanese atomic-bomb survivors: 60 years after exposure. Int J Cancer 2013, 132:1222-1226.
15. Kikuchi S., Perrier N.D., Ituarte P., Siperstein A.E., Duh Q.Y., Clark O.H. Latency period of thyroid neoplasia after radiation exposure. Ann Surg 2004, 239:536-543.
16. Calandra D.B., Shah K.H., Lawrence A.M., Paloyan E. Total thyroidectomy in irradiated patients. A twenty-year experience in 206 patients. Ann Surg 1985, 202:356-360.
17. Bhatti P., Veiga L.H., Ronckers C.M., et al. Risk of second primary thyroid cancer after radiotherapy for a childhood cancer in a large cohort study: an update from the childhood cancer survivor study. Radiat Res 2010, 174:741-752.
18. Grossman R.F., Tu S.H., Duh Q.Y., Siperstein A.E., Novosolov F., Clark O.H. Familial nonmedullary thyroid cancer. An emerging entity that warrants aggressive treatment. Arch Surg 1995, 130:892-897. [discussion 98-9].
19. Lupoli G., Vitale G., Caraglia M., et al. Familial papillary thyroid microcarcinoma: a new clinical entity. Lancet 1999, 353:637-639.
20. Uchino S., Noguchi S., Kawamoto H., et al. Familial nonmedullary thyroid carcinoma characterized by multifocality and a high recurrence rate in a large study population. World J Surg 2002, 26:897-902.
21. Ito Y., Fukushima M., Yabuta T., et al. Prevalence and prognosis of familial follicular thyroid carcinoma. Endocr J 2008, 55:847-852.
22. Maxwell E.L., Hall F.T., Freeman J.L. Familial non-medullary thyroid cancer: a matched-case control study. Laryngoscope 2004, 114:2182-2186.
23. Jarrar A.M., Milas M., Mitchell J., et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011, 253:515-521.
24. Tan M.H., Mester J.L., Ngeow J., Rybicki L.A., Orloff M.S., Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012, 18:400-407.
25. Pal T., Vogl F.D., Chappuis P.O., et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab 2001, 86:5307-5312.
26. Hemminki K., Eng C., Chen B. Familial risks for nonmedullary thyroid cancer. J Clin Endocrinol Metab 2005, 90:5747-5753.
27. Jin J., McHenry C.R. Thyroid incidentaloma. Best Pract Res Clin Endocrinol Metab 2012, 26:83-96.
28. Jin J., Wilhelm S.M., McHenry C.R. Incidental thyroid nodule: patterns of diagnosis and rate of malignancy. Am J Surg 2009, 197:320-324.
29. Ko H.M., Jhu I.K., Yang S.H., et al. Clinicopathologic analysis of fine needle aspiration cytology of the thyroid. A review of 1,613 cases and correlation with histopathologic diagnoses. Acta Cytol 2003, 47:727-732.
30. Mittendorf E.A., Khiyami A., McHenry C.R. When fine-needle aspiration biopsy cannot exclude papillary thyroid cancer: a therapeutic dilemma. Arch Surg 2006, 141:961-966. [discussion 66].
31. Sclabas G.M., Staerkel G.A., Shapiro S.E., et al. Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. Am J Surg 2003, 186:702-709. [discussion 09-10].
32. Chen H., Zeiger M.A., Clark D.P., Westra W.H., Udelsman R. Papillary carcinoma of the thyroid: can operative management be based solely on fine-needle aspiration?. J Am Coll Surg 1997, 184:605-610.
33. Boelaert K., Horacek J., Holder R.L., Watkinson J.C., Sheppard M.C., Franklyn J.A. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab 2006, 91:4295-4301.
34. Haymart M.R., Glinberg S.L., Liu J., Sippel R.S., Jaume J.C., Chen H. Higher serum TSH in thyroid cancer patients occurs independent of age and correlates with extrathyroidal extension. Clin Endocrinol 2009, 71:434-439.
35. McLeod D.S., Watters K.F., Carpenter A.D., Ladenson P.W., Cooper D.S., Ding E.L. Thyrotropin and thyroid cancer diagnosis: a systematic review and dose-response meta-analysis. J Clin Endocrinol Metab 2012, 97:2682-2692.
36. Kim S.S., Lee B.J., Lee J.C., et al. Preoperative serum thyroid stimulating hormone levels in well-differentiated thyroid carcinoma is a predictive factor for lateral lymph node metastasis as well as extrathyroidal extension in Korean Patients: a single-center experience. Endocrine 2011, 39:259-265.
37. Haymart M.R., Repplinger D.J., Leverson G.E., et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008, 93:809-814.
38. Grebe S.K., Hay I.D. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am 1996, 5:43-63.
39. Scheumann G.F., Gimm O., Wegener G., Hundeshagen H., Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg 1994, 18:559-567. [discussion 67-8].
40. Shaha A.R., Shah J.P., Loree T.R. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996, 3:534-538.
41. Cady B. Hayes Martin Lecture. Our AMES is true: how an old concept still hits the mark: or, risk group assignment points the arrow to rational therapy selection in differentiated thyroid cancer. Am J Surg 1997, 174:462-468.
42. NCCN. 'Guideline for Papillary Thyroid Carcinoma from National Cancer Center Network'. 〈〉; 2012. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp-thyroid .
43. Cooper D.S., Doherty G.M., et al. Revised American Thyroid Association Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214. American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer.
44. Cobin R.H., Gharib H., Bergman D.A., et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001, 7:202-220.
45. Katoh R., Sasaki J., Kurihara H., Suzuki K., Iida Y., Kawaoi A. Multiple thyroid involvement (intraglandular metastasis) in papillary thyroid carcinoma. A clinicopathologic study of 105 consecutive patients. Cancer 1992, 70:1585-1590.
46. Hay I.D., Grant C.S., Bergstralh E.J., et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid cancer?. Surgery 1998, 124(6):958-964. [discussion 64-6].
47. Bilimoria K.Y., Bentrem D.J., Ko C.Y., et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg 2007, 246:375-381. [discussion 81-4].
48. Barney B.M., Hitchcock Y.J., Sharma P., Shrieve D.C., Tward J.D. Overall and cause-specific survival for patients undergoing lobectomy, near-total, or total thyroidectomy for differentiated thyroid cancer. Head Neck 2011, 33:645-649.
49. Jonklaas J., Sarlis N.J., Litofsky D., et al. Outcomes of patients with differentiated thyroid carcinoma following initial therapy. Thyroid 2006, 16:1229-1242.
50. Mazzaferri E.L. Thyroid carcinoma: papillary and follicular. Endocrine Tumors 1993, Blackwell Scientific Publications Inc, Cambridge, MA. E.L. Mazzaferri, N. Samaan (Eds.).
51. Ito Y., Miyauchi A., Inoue H., et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg 2010, 34:28-35.
52. Scheumann G.F., Seeliger H., Musholt T.J., et al. Completion thyroidectomy in 131 patients with differentiated thyroid carcinoma. Eur J Surg 1996, 162:677-684.
53. Kobayashi T., Asakawa H., Tamaki Y., Umeshita K., Monden M. Fatal differentiated thyroid cancer. J Surg Oncol 1996, 62:123-127.
54. Martins A.S., Melo G.M., Valerio J.B., Langner E., Lage H.T., Tincani A.J. Treatment of locally aggressive well-differentiated thyroid cancer. Int Surg 2001, 86:213-219.
55. Falk S.A., McCaffrey T.V. Management of the recurrent laryngeal nerve in suspected and proven thyroid cancer. Otolaryngol Head Neck Surg 1995, 113:42-48.
56. McHenry C.R., Phitayakorn R. Difficult problems in thyroid cancer surgery. Minerva Chir 2010, 65:83-93.
57. Shaha A.R. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope 2004, 114:393-402.
58. Schlumberger M.J. Papillary and follicular thyroid carcinoma. N Engl J Med 1998, 338:297-306.
59. Noguchi S., Murakami N. The value of lymph-node dissection in patients with differentiated thyroid cancer. Surg Clin North Am 1987, 67:251-261.
60. Kouvaraki M.A., Shapiro S.E., Fornage B.D., et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery 2003, 134:946-954. [discussion 54-5].
61. Stulak J.M., Grant C.S., Farley D.R., et al. Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. Arch Surg 2006, 141:489-494. [discussion 94-6].
62. Choi Y.J., Yun J.S., Kook S.H., Jung E.C., Park Y.L. Clinical and imaging assessment of cervical lymph node metastasis in papillary thyroid carcinomas. World J Surg 2010, 34:1494-1499.
63. Roh J.L., Kim J.M., Park C.I. Lateral cervical lymph node metastases from papillary thyroid carcinoma: pattern of nodal metastases and optimal strategy for neck dissection. Ann Surg Oncol 2008, 15:1177-1182.
64. Machens A., Hauptmann S., Dralle H. Lymph node dissection in the lateral neck for completion in central node-positive papillary thyroid cancer. Surgery 2009, 145:176-181.
65. Lundgren C.I., Hall P., Dickman P.W., Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer 2006, 106:524-531.
66. Podnos Y.D., Smith D., Wagman L.D., Ellenhorn J.D. The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. Am Surg 2005, 71:731-734.
67. Tisell L.E., Nilsson B., Molne J., et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996, 20:854-859.
68. White M.L., Gauger P.G., Doherty G.M. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007, 31:895-904.
69. Cranshaw I.M., Carnaille B. Micrometastases in thyroid cancer. An important finding?. Surg Oncol 2008, 17:253-258.
70. Teixeira G., Teixeira T., Gubert F., Chikota H., Tufano R. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. Surgery 2011, 150:1161-1167.
71. Hughes D.T., Doherty G.M. Central neck dissection for papillary thyroid cancer. Cancer Control 2011, 18:83-88.
72. Zetoune T., Keutgen X., Buitrago D., et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol 2010, 17:3287-3293.
73. Turanli S. Is the type of dissection in lateral neck metastasis for differentiated thyroid carcinoma important?. Otolaryngol Head Neck Surg 2007, 136:957-960.
74. Caron N.R., Tan Y.Y., Ogilvie J.B., et al. Selective modified radical neck dissection for papillary thyroid cancer-is level I, II and V dissection always necessary?. World J Surg 2006, 30:833-840.
75. Daniels G.H. What if many follicular variant papillary thyroid carcinomas are not malignant? A review of follicular variant papillary thyroid carcinoma and a proposal for a new classification. Endocr Pract 2011, 17:768-787.
76. Rosai J., Kuhn E., Carcangiu M.L. Pitfalls in thyroid tumour pathology. Histopathology 2006, 49:107-120.
77. Chan J.K. Strict criteria should be applied in the diagnosis of encapsulated follicular variant of papillary thyroid carcinoma. Am J Clin Pathol 2002, 117:16-18.
78. Lin H.W., Bhattacharyya N. Clinical behavior of follicular variant of papillary thyroid carcinoma: presentation and survival. Laryngoscope 2010, 120:712-716.
79. Liu J., Singh B., Tallini G., et al. Follicular variant of papillary thyroid carcinoma: a clinicopathologic study of a problematic entity. Cancer 2006, 107:1255-1264.
80. Ghossein R., Livolsi V.A. Papillary thyroid carcinoma tall cell variant. Thyroid 2008, 18:1179-1181.
81. Sobrinho-Simoes M.A., Nesland J.M., Holm R., Sambade M.C., Johannessen J.V. Hurthle cell and mitochondrion-rich papillary carcinomas of the thyroid gland: an ultrastructural and immunocytochemical study. Ultrastruct Pathol 1985, 8:131-142.
82. Chan J.K. Tumors of the Thyroid and Parathyroid Glands. The Thyroid Gland. Part A. 2 ed. Vol. 2, Diagnostic Histopathology of Tumors 2000, Churchill, Livingston, London.
83. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007, 28:742-762.
84. Groussin L., Fagin J.A. Significance of BRAF mutations in papillary thyroid carcinoma: prognostic and therapeutic implications. Nat Clin Pract Endocrinol Metab 2006, 2:180-181.
85. Adeniran A.J., Zhu Z., Gandhi M., et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006, 30:216-222.
86. Thompson L.D., Wieneke J.A., Heffess C.S. Diffuse sclerosing variant of papillary thyroid carcinoma: a clinicopathologic and immunophenotypic analysis of 22 cases. Endocr Pathol 2005, 16:331-348.
87. Chow S.M., Chan J.K., Law S.C., et al. Diffuse sclerosing variant of papillary thyroid carcinoma-Clinical features and outcome. Eur J Surg Oncol 2003, 29:446-449.
88. Carcangiu M.L., Bianchi S. Diffuse sclerosing variant of papillary thyroid carcinoma. Clinicopathologic study of 15 cases. Am J Surg Pathol 1989, 13:1041-1049.
89. Uchino S., Noguchi S., Yamashita H., et al. Mutational analysis of the APC gene in cribriform-morula variant of papillary thyroid carcinoma. World J Surg 2006, 30:775-779.
90. Xu B., Yoshimoto K., Miyauchi A., et al. Cribriform-morular variant of papillary thyroid carcinoma: a pathological and molecular genetic study with evidence of frequent somatic mutations in exon 3 of the beta-catenin gene. J Pathol 2003, 199:58-67.
91. Nikiforov Y.E. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol 2008, 21(suppl 2):S37-S43.
92. Romei C., Fugazzola L., Puxeddu E., et al. Modifications in the papillary thyroid cancer gene profile over the last 15 years. J Clin Endocrinol Metab 2012, 97:E1758-E1765.
93. Nikiforov Y.E., Ohori N.P., Hodak S.P., et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab 2011, 96:3390-3397.
94. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005, 12:245-262.
95. Kim T.H., Park Y.J., Lim J.A., et al. The association of the BRAF(V600e) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012, 118:1764-1773.
96. Sarne D.H. A piece of the puzzle: what does braf status mean in the management of patients with papillary thyroid carcinoma?. J Clin Endocrinol Metab 2012, 97:3094-3096.
97. Nikiforova M.N., Kimura E.T., Gandhi M., et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003, 88:5399-5404.
98. Nikiforov Y.E., Steward D.L., Robinson-Smith T.M., et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab 2009, 94:2092-2098.
99. Melck A.L., Yip L., Carty S.E. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist 2010, 15:1285-1293.
100. Lupi C., Giannini R., Ugolini C., et al. Association of BRAF V600e mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92:4085-4090.
101. Kebebew E., Weng J., Bauer J., et al. The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg 2007, 246:466-470. [discussion 70-1].
102. Sancisi V., Nicoli D., Ragazzi M., Piana S., Ciarrocchi A. BRAFV600E mutation does not mean distant metastasis in thyroid papillary carcinomas. J Clin Endocrinol Metab 2012, 97:E1745-E1749.
103. Hundahl S.A., Fleming I.D., Fremgen A.M., Menck H.R.A. National Cancer Data Base Report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [See Comments]. Cancer 1998, 83:2638-2648.
104. Society AC. 'Thyroid Cancer Survival by Type and Stage'. 〈〉; 2012. http://www.cancer.org/cancer/thyroidcancer/detailedguide/thyroid-cancer- survival-rates.
105. Tran Cao H.S., Johnston L.E., Chang D.C., Bouvet M.A. Critical analysis of the American Joint Committee on Cancer (AJCC) staging system for differentiated thyroid carcinoma in young patients on the basis of the Surveillance, Epidemiology, and End Results (SEER) Registry. Surgery 2012, 152:145-151.
106. Ruegemer J.J., Hay I.D., Bergstralh E.J., Ryan J.J., Offord K.P., Gorman C.A. Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 1988, 67:501-508.
107. Brennan M.D., Bergstralh E.J., van Heerden J.A., McConahey W.M. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1991, 66:11-22.
108. McHenry C.R., Thomas S.R., Slusarczyk S.J., Khiyami A. Follicular or Hurthle cell neoplasm of the thyroid: can clinical factors be used to predict carcinoma and determine extent of thyroidectomy?. Surgery 1999, 126:798-802. [discussion 02-4].
109. Iared W., Shigueoka D.C., Cristofoli J.C., et al. Use of color Doppler ultrasonography for the prediction of malignancy in follicular thyroid neoplasms: systematic review and meta-analysis. J Ultrasound Med 2010, 29:419-425.
110. McHenry C.R., Slusarczyk S.J., Askari A.T., et al. Refined use of scintigraphy in the evaluation of nodular thyroid disease. Surgery 1998, 124:656-661. [discussion 61-2].
111. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr Pathol 2004, 15:319-327.
112. J.Downward Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3:11-22.
113. Medema R.H., Bos J.L. The role of p21ras in receptor tyrosine kinase signaling. Crit Rev Oncog 1993, 4:615-661.
114. Martelli M.L., Iuliano R., Le Pera I., et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002, 87:4728-4735.
115. Weber F., Teresi R.E., Broelsch C.E., Frilling A., Eng C. A limited set of human microrna is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006, 91:3584-3591.
116. Fuhrer D., Tannapfel A., Sabri O., Lamesch P., Paschke R. Two somatic TSH receptor mutations in a patient with toxic metastasising follicular thyroid carcinoma and non-functional lung metastases. Endocr Relat Cancer 2003, 10:591-600.
117. Chudova D., Wilde J.I., Wang E.T., et al. Molecular classification of thyroid nodules using high-dimensionality genomic data. J Clin Endocrinol Metab 2010, 95:5296-5304.
118. Alexander E.K., Kennedy G.C., Baloch Z.W., et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med 2012, 367:705-715.
119. Chinnappa P., Taguba L., Arciaga R., et al. Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. J Clin Endocrinol Metab 2004, 89:3705-3709.
120. Milas M., Shin J., Gupta M., et al. Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: clinical applications learned from 1758 samples. Ann Surg 2010, 252:643-651.
121. Ghossein R. Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med 2009, 133:683-691.
122. D'Avanzo A., Treseler P., Ituarte P.H., et al. Follicular thyroid carcinoma: histology and prognosis. Cancer 2004, 100:1123-1129.
123. van Heerden J.A., Hay I.D., Goellner J.R., et al. Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. Surgery 1992, 112:1130-1136. [discussion 36-8].
124. Sanders L.E., Silverman M. Follicular and Hurthle cell carcinoma: predicting outcome and directing therapy. Surgery 1998, 124:967-974.
125. McHenry C.R., Raeburn C., Strickland T., Marty J.J. The utility of routine frozen section examination for intraoperative diagnosis of thyroid cancer. Am J Surg 1996, 172:658-661.
126. Thompson L.D., Wieneke J.A., Paal E., Frommelt R.A., Adair C.F., Heffess C.S.A. Clinicopathologic study of minimally invasive follicular carcinoma of the thyroid gland with a review of the English literature. Cancer 2001, 91:505-524.
127. Johnson T.L., Lloyd R.V., Burney R.E., Thompson N.W. Hurthle cell thyroid tumors. an immunohistochemical study. Cancer 1987, 59:107-112.
128. Clark O.H., Gerend P.L. Thyrotropin receptor-adenylate cyclase system in Hurthle cell neoplasms. J Clin Endocrinol Metab 1985, 61:773-778.
129. Montone K.T., Baloch Z.W., LiVolsi V.A. The thyroid Hurthle (oncocytic) cell and its associated pathologic conditions: a surgical pathology and cytopathology review. Arch Pathol Lab Med 2008, 132:1241-1250.
130. Lopez-Penabad L., Chiu A.C., Hoff A.O., et al. Prognostic factors in patients with Hurthle cell neoplasms of the thyroid. Cancer 2003, 97:1186-1194.
131. Kushchayeva Y., Duh Q.Y., Kebebew E., D'Avanzo A., Clark O.H. Comparison of clinical characteristics at diagnosis and during follow-up in 118 patients with Hurthle cell or follicular thyroid cancer. Am J Surg 2008, 195:457-462.
132. Soh E.Y., Clark O.H. Surgical considerations and approach to thyroid cancer. Endocrinol Metab Clin North Am 1996, 25:115-139.
133. Maxon H.R., Smith H.S. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990, 19:685-718.
134. Alaedeen D.I., Khiyami A., McHenry C.R. Fine-needle aspiration biopsy specimen with a predominance of Hurthle cells: a dilemma in the management of nodular thyroid disease. Surgery 2005, 138:650-656. [discussion 56-7].
135. Carcangiu M.L., Bianchi S., Savino D., Voynick I.M., Rosai J. Follicular Hurthle cell tumors of the thyroid gland. Cancer 1991, 68:1944-1953.
136. Melck A., Bugis S., Baliski C., et al. Hemithyroidectomy: the preferred initial surgical approach for management of Hurthle cell neoplasm. Am J Surg 2006, 191:593-597.
137. Chen H., Nicol T.L., Udelsman R. Follicular lesions of the thyroid. Does frozen section evaluation alter operative management?. Ann Surg 1995, 222:101-106.
138. Dumont J.E. The action of thyrotropin on thyroid metabolism. Vitam Horm 1971, 29:287-412.
139. Roger P., Taton M., Van Sande J., Dumont J.E. Mitogenic effects of thyrotropin and adenosine 3',5'-monophosphate in differentiated normal human thyroid cells in vitro. J Clin Endocrinol Metab 1988, 66:1158-1165.
140. Pujol P., Daures J.P., Nsakala N., Baldet L., Bringer J., Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996, 81:4318-4323.
141. Cooper D.S., Specker B., Ho M., et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998, 8:737-744.
142. Mazzaferri E.L., Kloos R.T. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:1447-1463.
143. Biondi B., Filetti S., Schlumberger M. Thyroid-hormone therapy and thyroid cancer: a reassessment. Nat Clin Pract Endocrinol Metab 2005, 1:32-40.
144. Pacini F., Schlumberger M., Dralle H., et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154:787-803.
145. Pacini F., Castagna M.G. Diagnostic and therapeutic use of recombinant human TSH (RHTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 2008, 22:1009-1021.
146. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50mCi) and 3700 MBq (100mCi) 131-Iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92:3542-3546.
147. Pacini F., Molinaro E., Castagna M.G., et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002, 87:4063-4068.
148. Mazzaferri E.L., Robbins R.J., Spencer C.A., et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003, 88:1433-1441.
149. Haugen B.R., Pacini F., Reiners C., et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999, 84:3877-3885.
150. Spencer C.A. Clinical review: clinical utility of thyroglobulin antibody (TGAB) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011, 96:3615-3627.
151. Kumar A., Shah D.H., Shrihari U., Dandekar S.R., Vijayan U., Sharma S.M. Significance of antithyroglobulin autoantibodies in differentiated thyroid carcinoma. Thyroid 1994, 4:199-202.
152. Chindris A.M., Diehl N.N., Crook J.E., Fatourechi V., Smallridge R.C. Undetectable sensitive serum thyroglobulin (<0.1ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of RHTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up. J Clin Endocrinol Metab 2012, 97:2714-2723.
153. Schlumberger M., Hitzel A., Toubert M.E., et al. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. J Clin Endocrinol Metab 2007, 92:2487-2495.
154. Spencer C., Fatemi S., Singer P., Nicoloff J., Lopresti J. Serum basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Thyroid 2010, 20:587-595.
155. Malandrino P. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab 2011, 96:1703-1709.
156. 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006, 91:60-63.
157. Durante C., Montesano T., Attard M., et al. Long-term surveillance of papillary thyroid cancer patients who do not undergo postoperative radioiodine remnant ablation: is there a role for serum thyroglobulin measurement?. J Clin Endocrinol Metab 2012, 97:2748-2753.
158. Gorges R., Maniecki M., Jentzen W., et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy. Eur J Endocrinol 2005, 153:49-55.
159. Kim W.G., Yoon J.H., Kim W.B., et al. Change of serum antithyroglobulin antibody levels is useful for prediction of clinical recurrence in thyroglobulin-negative patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 2008, 93:4683-4689.
160. van Tol K.M., Jager P.L., de Vries E.G., et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. Eur J Endocrinol 2003, 148:589-596.
161. Wang W., Macapinlac H., Larson S.M., et al. [18F]-2-Fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999, 84:2291-2302.
162. Lind P., Kresnik E., Kumnig G., et al. 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 2003, 30:17-21.
163. Larson S.M., Robbins R. Positron emission tomography in thyroid cancer management. Semin Roentgenol 2002, 37:169-174.
164. Hooft L., Hoekstra O.S., Deville W., et al. Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86:3779-3786.
165. Leboulleux S., Schroeder P.R., Busaidy N.L., et al. Assessment of the incremental value of recombinant thyrotropin stimulation before 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography imaging to localize residual differentiated thyroid cancer. J Clin Endocrinol Metab 2009, 94:1310-1316.
166. Nagamachi S., Wakamatsu H., Kiyohara S., et al. Comparison of diagnostic and prognostic capabilities of (1)(8)F-FDG-PET/CT, (1)(3)(1)I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol 2011, 29:413-422.
167. Schreinemakers J.M., Vriens M.R., Munoz-Perez N., et al. Fluorodeoxyglucose-positron emission tomography scan-positive recurrent papillary thyroid cancer and the prognosis and implications for surgical management. World J Surg Oncol 2012, 10:192.
168. Zoller M., Kohlfuerst S., Igerc I., et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. Eur J Nucl Med Mol Imaging 2007, 34:487-495.
169. Freudenberg L.S., Frilling A., Kuhl H., et al. Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 2007, 17:3139-3147.
170. Seiboth L., Van Nostrand D., Wartofsky L., Ousman Y., Jonklaas J., Butler C., et al. Utility of PET/neck MRI digital fusion images in the management of recurrent or persistent thyroid cancer. Thyroid 2008, 18:103-111.
171. Nagaiah G., Hossain A., Mooney C.J., Parmentier J., Remick S.C. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J Oncol 2011, 2011:542358.
172. Schlumberger M., Challeton C., De Vathaire F., et al. Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 1996, 37:598-605.
173. Shoup M., Stojadinovic A., Nissan A., et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003, 197:191-197.
174. Tala H., Robbins R., Fagin J.A., Larson S.M., Tuttle R.M. Five-year survival is similar in thyroid cancer patients with distant metastases
175. Casara D., Rubello D., Saladini G., et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993, 34:1626-1631.
176. Durante C., Haddy N., Baudin E., et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006, 91:2892-2899.
177. Haugen B.R., Kane M.A. Approach to the thyroid cancer patient with extracervical metastases. J Clin Endocrinol Metab 2010, 95:987-993.
178. Tuttle R.M., Leboeuf R., Robbins R.J., et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med 2006, 47:1587-1591.
179. Porterfield J.R., Cassivi S.D., Wigle D.A., et al. Thoracic metastasectomy for thyroid malignancies. Eur J Cardiothorac Surg 2009, 36:155-158.
180. Bernier M.O., Leenhardt L., Hoang C., et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab 2001, 86:1568-1573.
181. Schmidt G.P., Schoenberg S.O., Schmid R., et al. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT. Eur Radiol 2007, 17:939-949.
182. Kloos R.T., Eng C., et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009, 19:565-612. American Thyroid Association Guidelines Task Force.
183. Chiu A.C., Delpassand E.S., Sherman S.I. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab 1997, 82:3637-3642.
184. Ronga G., Filesi M., Montesano T., et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. Q J Nucl Med Mol Imaging 2004, 48:12-19.
185. Kloos R.T., Ringel M.D., Knopp M.V., et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009, 27:1675-1684.
186. O'Neill C.J., Oucharek J., Learoyd D., Sidhu S.B. Standard and emerging therapies for metastatic differentiated thyroid cancer. Oncologist 2010, 15:146-156.
187. Sherman S.I. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009, 23:713-722.
188. Zarnegar R., Brunaud L., Kanauchi H., et al. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002, 132:984-990. [discussion 90].
189. Muller K., Fuhrer D., Mittag J., et al. TSH compensates thyroid-specific IGF-I receptor knockout and causes papillary thyroid hyperplasia. Mol Endocrinol 2011, 25:1867-1879.
190. Malaguarnera R., Frasca F., Garozzo A., et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab 2011, 96:766-774.
191. Smallridge R.C., Copland J.A. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol 2010, 22:486-497.
192. Cornett W.R., Sharma A.K., Day T.A., et al. Anaplastic thyroid carcinoma: an overview. Curr Oncol Rep 2007, 9:152-158.
193. Pasieka J.L. Anaplastic thyroid cancer. Curr Opin Oncol 2003, 15:78-83.
194. Are C., Shaha A.R. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006, 13:453-464.
195. Trimboli P., Ulisse S., Graziano F.M., et al. Trend in thyroid carcinoma size, age at diagnosis, and histology in a retrospective study of 500 cases diagnosed over 20 years. Thyroid 2006, 16:1151-1155.
196. Besic N., Hocevar M., Zgajnar J. Lower incidence of anaplastic carcinoma after higher iodination of salt in Slovenia. Thyroid 2010, 20:623-626.
197. Broome J.T., Gauger P.G., Miller B.S., Doherty G.M. Anaplastic thyroid cancer manifesting as new-onset Horner syndrome. Endocr Pract 2009, 15:563-566.
198. McIver B., Hay I.D., Giuffrida D.F., et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001, 130:1028-1034.
199. Smallridge R. Approach to the patient with anaplastic thyroid cancer. J Clin Endocrinol Metab 2012, 97:2566-2572.
200. Smallridge R.C. Approach to the patient with anaplastic thyroid carcinoma. J Clin Endocrinol Metab 2012, 97:2566-2572.
201. Bishop J.A., Sharma R., Westra W.H. PAX8 immunostaining of anaplastic thyroid carcinoma: a reliable means of discerning thyroid origin for undifferentiated tumors of the head and neck. Hum Pathol 2011, 42:1873-1877.
202. Neff R.L., Farrar W.B., Kloos R.T., Burman K.D. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008, 37:525-538. [xi].
203. Poisson T., Deandreis D., Leboulleux S., et al. 18F-fluorodeoxyglucose positron emission tomography and computed tomography in anaplastic thyroid cancer. Eur J Nucl Med Mol Imaging 2010, 37:2277-2285.
204. Sherman E.J., Lim S.H., Ho A.L., et al. Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: a critical re-evaluation including uniform pathologic review. Radiother Oncol 2011, 101:425-430.
205. Tennvall J., Lundell G., Wahlberg P., et al. Anaplastic thyroid carcinoma: three protocols combining doxorubicin, hyperfractionated radiotherapy and surgery. Br J Cancer 2002, 86:1848-1853.
206. Foote R.L., Molina J.R., Kasperbauer J.L., et al. Enhanced survival in locoregionally confined anaplastic thyroid carcinoma: a single-institution experience using aggressive multimodal therapy. Thyroid 2010, 21:25-30.
207. Akaishi J., Sugino K., Kitagawa W., et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011, 21:1183-1189.
208. Nehs M.A., Lin C.I., Kozono D.E., et al. Necroptosis is a novel mechanism of radiation-induced cell death in anaplastic thyroid and adrenocortical cancers. Surgery 2011, 150:1032-1039.
209. Kim J.H., Leeper R.D. Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. Cancer 1987, 60:2372-2375.
210. Wong C.S., Van Dyk J., Simpson W.J. Myelopathy following hyperfractionated accelerated radiotherapy for anaplastic thyroid carcinoma. Radiother Oncol 1991, 20:3-9.
211. Dandekar P., Harmer C., Barbachano Y., et al. Hyperfractionated accelerated radiotherapy (HART) for anaplastic thyroid carcinoma: toxicity and survival analysis. Int J Radiat Oncol Biol Phys 2009, 74:518-521.
212. Schwartz D.L., Lobo M.J., Ang K.K., et al. Postoperative external beam radiotherapy for differentiated thyroid cancer: outcomes and morbidity with conformal treatment. Int J Radiat Oncol Biol Phys 2009, 74:1083-1091.
213. Higashiyama T., Ito Y., Hirokawa M., et al. Induction chemotherapy with weekly paclitaxel administration for anaplastic thyroid carcinoma. Thyroid 2010, 20:7-14.
214. Catalano M.G., Fortunati N., Pugliese M., et al. Histone deacetylase inhibition modulates E-cadherin expression and suppresses migration and invasion of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 2012, 97:E1150-E1159.
215. Ooi M.G., Hayden P.J., Kotoula V., McMillin D.W., Charalambous E., Daskalaki E., et al. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 2009, 15:7153-7160.
216. Prichard C.N., Kim S., Yazici Y.D., et al. Concurrent cetuximab and bevacizumab therapy in a murine orthotopic model of anaplastic thyroid carcinoma. Laryngoscope 2007, 117:674-679.
217. Kim E., Matsuse M., Saenko V., et al. Imatinib enhances docetaxel-induced apoptosis through inhibition of nuclear factor-kappaB activation in anaplastic thyroid carcinoma cells. Thyroid 2012, 22:717-724.
218. Perri F., Lorenzo G.D., Scarpati G.D., Buonerba C. Anaplastic thyroid carcinoma: a comprehensive review of current and future therapeutic options. World J Clin Oncol 2011, 2:150-157.
219. Chen J., Tward J.D., Shrieve D.C., Hitchcock Y.J. Surgery and radiotherapy improves survival in patients with anaplastic thyroid carcinoma: analysis of the surveillance, epidemiology, and end results 1983-2002. Am J Clin Oncol 2008, 31:460-464.
220. Tan R.K., Finley R.K., Driscoll D., Bakamjian V., Hicks W.L., Shedd D.P. Anaplastic carcinoma of the thyroid: a 24-year experience. Head Neck 1995, 17:41-47. [discussion 47-8].
221. Gilliland F.D., Hunt W.C., Morris D.M., Key C.R. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the surveillance, epidemiology and end results (SEER) program 1973-1991. Cancer 1997, 79:564-573.
222. Lo C.Y., Lam K.Y., Wan K.Y. Anaplastic carcinoma of the thyroid. Am J Surg 1999, 177:337-339.
223. Sugitani I., Kasai N., Fujimoto Y., Yanagisawa A. Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid. World J Surg 2001, 25:617-622.
224. Orita Y., Sugitani I., Amemiya T., Fujimoto Y. Prospective application of our novel prognostic index in the treatment of anaplastic thyroid carcinoma. Surgery 2011, 150:1212-1219.
225. Kitamura Y., Shimizu K., Nagahama M., et al. Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J Clin Endocrinol Metab 1999, 84:4043-4049.
226. Hazard J.B., Hawk W.A., Crile G. Medullary (solid) carcinoma of the thyroid; a clinicopathologic entity. J Clin Endocrinol Metab 1959, 19:152-161.
227. Williams E.D. Histogenesis of medullary carcinoma of the thyroid. J Clin Pathol 1966, 19:114-118.
228. Chen H., Sippel R.S., O'Dorisio M.S., Vinik A.I., Lloyd R.V., Pacak K. The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas 2010, 39:775-783.
229. Cohen M.S., Moley J.F. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003, 253:616-626.
230. Wiench M., Wygoda Z., Gubala E., et al. Estimation of risk of inherited medullary thyroid carcinoma in apparent sporadic patients. J Clin Oncol 2001, 19:1374-1380.
231. Eng C., Clayton D., Schuffenecker I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. J Am Med Assoc 1996, 276:1575-1579.
232. Machens A., Hauptmann S., Dralle H. Modification of multiple endocrine neoplasia 2A phenotype by cell membrane proximity of RET mutations in exon 10. Endocr Relat Cancer 2009, 16:171-177.
233. Farndon J.R., Leight G.S., Dilley W.G., et al. Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg 1986, 73:278-281.
234. Callender G.G., Rich T.A., Perrier N.D. Multiple endocrine neoplasia syndromes. Surg Clin North Am 2008, 88:863-895. [viii].
235. Carlson K.M., Bracamontes J., Jackson C.E., et al. Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 1994, 55:1076-1082.
236. Colombo C., Verga U., Mian C., et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab 2012, 97:905-913.
237. Machens A., Schneyer U., Holzhausen H.J., Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005, 90:2029-2034.
238. Moo-Young T.A., Traugott A.L., Moley J.F. Sporadic and familial medullary thyroid carcinoma: state of the art. Surg Clin North Am 2009, 89:1193-1204.
239. Machens A., Ukkat J., Brauckhoff M., Gimm O., Dralle H. Advances in the management of hereditary medullary thyroid cancer. J Intern Med 2005, 257:50-59.
240. Brandi M.L., Gagel R.F., Angeli A., et al. Guidelines for diagnosis and therapy of men type 1 and type 2. J Clin Endocrinol Metab 2001, 86:5658-5671.
241. Hamy A., Pessaux P., Mirallie E., et al. Central neck dissection in the management of sporadic medullary thyroid microcarcinoma. Eur J Surg Oncol 2005, 31:774-777.
242. Machens A., Hauptmann S., Dralle H. Increased risk of lymph node metastasis in multifocal hereditary and sporadic medullary thyroid cancer. World J Surg 2007, 31:1960-1965.
243. Moley J.F., DeBenedetti M.K. Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880-887. [discussion 87-8].
244. Scollo C., Baudin E., Travagli J.P., et al. Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2003, 88:2070-2075.
245. Dackiw A.P. The surgical management of medullary thyroid cancer. Otolaryngol Clin North Am 2010, 43:365. [ix].
246. Greene F.L.P.D., Fleming I.D., Fritz A., Balch D.M. Ajcc Cancer Staging Manual 2003, Springer Verlag, Chicago. 6th ed.
247. Modigliani E., Cohen R., Campos J.M., et al. Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol 1998, 48:265-273.
248. Cheng X., Bao L., Xu Z., Li D., Wang J., Li Y. (1)(8)F-FDG-PET and (1)(8)F-FDG-PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: a systematic review and meta-analysis. J Med Imaging Radiat Oncol 2012, 56:136-142.
249. Skoura E., Rondogianni P., Alevizaki M., et al. Role of [(18)F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer. Nucl Med Commun 2010, 31:567-575.
250. Schwartz D.L., Rana V., Shaw S., et al. Postoperative radiotherapy for advanced medullary thyroid cancer-local disease control in the modern era. Head Neck 2008, 30:883-888.
251. Brierley J., Tsang R., Simpson W.J., Gospodarowicz M., Sutcliffe S., Panzarella T. Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996, 6:305-310.
252. Martinez S.R., Beal S.H., Chen A., Chen S.L., Schneider P.D. Adjuvant external beam radiation for medullary thyroid carcinoma. J Surg Oncol 2010, 102:175-178.
253. Wells S.A., Gosnell J.E., Gagel R.F., et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28:767-772.
254. Ansell S.M., Grant C.S., Habermann T.M. Primary thyroid lymphoma. Semin Oncol 1999, 26:316-323.
255. Derringer G.A., Thompson L.D., Frommelt R.A., Bijwaard K.E., Heffess C.S., Abbondanzo S.L. Malignant lymphoma of the thyroid gland: a clinicopathologic study of 108 cases. Am J Surg Pathol 2000, 24:623-639.
256. Pedersen R.K., Pedersen N.T. Primary non-Hodgkin's lymphoma of the thyroid gland: a population based study. Histopathology 1996, 28:25-32.
257. Holm L.E., Blomgren H., Lowhagen T. Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 1985, 312:601-604.
258. Xian W., Ho K.Y., Crum C.P., McKeon F. Cellular origin of Barrett's esophagus: controversy and therapeutic implications. Gastroenterology 2012, 142:1424-1430.
259. Kossev P., Livolsi V. Lymphoid lesions of the thyroid: review in light of the revised European-American lymphoma classification and upcoming World Health Organization Classification. Thyroid 1999, 9:1273-1280.
260. Sangalli G., Serio G., Zampatti C., Lomuscio G., Colombo L. Fine needle aspiration cytology of primary lymphoma of the thyroid: a report of 17 cases. Cytopathology 2001, 12:257-263.
261. Cha C., Chen H., Westra W.H., Udelsman R. Primary thyroid lymphoma: can the diagnosis be made solely by fine-needle aspiration?. Ann Surg Oncol 2002, 9:298-302.
262. Mack L.A., Pasieka J.L. An evidence-based approach to the treatment of thyroid lymphoma. World J Surg 2007, 31:978-986.
263. Takashima S., Morimoto S., Ikezoe J., et al. Primary thyroid lymphoma: comparison of CT and US assessment. Radiology 1989, 171:439-443.
264. Pasieka J.L. Hashimoto's disease and thyroid lymphoma: role of the surgeon. World J Surg 2000, 24:966-970.
265. Grimley R.P., Oates G.D. The natural history of malignant thyroid lymphomas. Br J Surg 1980, 67:475-477.
266. Staunton M.D., Greening W.P. Treatment of thyroid cancer in 293 patients. Br J Surg 1976, 63:253-258.
267. Doria R., Jekel J.F., Cooper D.L. Thyroid lymphoma. The case for combined modality therapy. Cancer 1994, 73:200-206.
268. Ha C.S., Shadle K.M., Medeiros L.J., et al. Localized non-Hodgkin lymphoma involving the thyroid gland. Cancer 2001, 91:629-635.
269. Matsuzuka F., Miyauchi A., Katayama S., et al. Clinical aspects of primary thyroid lymphoma: diagnosis and treatment based on our experience of 119 cases. Thyroid 1993, 3:93-99.
270. Laing R.W., Hoskin P., Hudson B.V., et al. The significance of malt histology in thyroid lymphoma: a review of patients from the BNLI and Royal Marsden Hospital. Clin Oncol (R Coll Radiol) 1994, 6:300-304.
271. Zelenetz A.D., Advani R.H., Buadi F., et al. Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006, 4:258-310.
272. Sippel R.S., Gauger P.G., Angelos P., Thompson N.W., Mack E., Chen H. Palliative thyroidectomy for malignant lymphoma of the thyroid. Ann Surg Oncol 2002, 9:907-911.